LifeStance Reports Fourth Quarter and Full Year 2024 Results

Core Insights - LifeStance Health Group, Inc. reported strong financial performance for 2024, with a revenue growth of 19% year-over-year, reaching $1.251 billion, and a significant increase in Adjusted EBITDA by 103$119.7 million [3][5][6] Financial Highlights - Q4 2024 total revenue was $325.5 million, a 16$1,251.0 million, up from $1,055.7 million in 2023, marking a 19$32.8 million, a 62% increase from Q4 2023, and for the full year, it was $119.7 million [4][6][7] - The company reported a net loss of$7.1 million in Q4 2024, compared to a net loss of $45.0 million in Q4 2023, and a full year net loss of$57.4 million, down from $186.3 million in 2023 [4][5][6] Operational Metrics - The clinician base increased by 12$62.3 million, totaling $107.3 million for the full year [5][8] - The company ended Q4 2024 with cash of$154.6 million and net long-term debt of $279.8 million [8] 2025 Guidance - LifeStance expects full year 2025 revenue to be between$1.40 billion and $1.44 billion, with a Center Margin of$440 million to $464 million, and Adjusted EBITDA of$130 million to $150 million [5][13]